Recent approvals of Benlysta and Lupkynis highlight a shift towards targeted therapies with improved profiles. Despite challenges like high costs and heterogeneous disease presentation, opportunities ...

Researchers at the University Hospital Bonn (UKB) and the University of Bonn have discovered how a small, naturally occurring ...

These findings underscore the limitations of relying on proteinuria alone to assess LN treatment success and demonstrate the clinical utility of biomarker-guided risk stratification.

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Adicet Bio (ACET) to $9 from $4 and keeps a Buy rating on the shares. The ...

Kyverna Therapeutics, Inc. (($KYTX)) announced an update on their ongoing clinical study. Kyverna Therapeutics, Inc. is conducting a clinical ...

United States real-world studies highlight the importance of controlling lupus nephritis to improve patient prognosis.

Lupus nephritis is a serious complication of lupus that is caused by inflammation of the kidneys. It affects up to 60% of people with lupus and usually occurs within 5 years of diagnosis. If left ...

The use of existing guidelines for pediatric treatment varies significantly among sites, a new study has found. The study findingssuggest wide variation exists in the medications prescribed to treat ...

DelveInsight's Lupus Nephritis Market Insights report includes a comprehensive understanding of current treatment practices, lupus nephritis emerging drugs, market share of individual therapies, and ...

This transcript has been edited for clarity. Matthew A. Sparks, MD: I'm Dr Matthew Sparks, and welcome to Medscape's InDiscussion podcast series on chronic kidney disease. Today we'll be discussing ...

On the heels of last week’s lupus nephritis nod from the FDA, Roche’s Gazyva is proving once again that it still has new ...